IGHE and cancer: Although the use of IgE-class antibodies in anti-cancer therapy has been the focus of many pre-clinical studies (recently reviewed by Sutton et al.,5 Chauhan et al. 50), the fate and distribution of exogenous IgE-based drugs after administration remains unclear.